A late-stage trial found that Celgene's Revlimid, or lenalidomide, in combination with dexamethasone, was effective in delaying progression and extending survival in patients with high-risk asymptomatic smoldering myeloma. The drug is approved for the treatment of multiple myeloma and mantle cell lymphoma as well as for transfusion-dependent anemia related to certain myelodysplastic syndromes.

Full Story:
PharmaTimes (U.K.)

Related Summaries